T. Solomon1, M.D. Peake2, J. Butler3, M.P. Coleman1, W.K. Evans4, E. Jakobsen5, M. Boyer6, T.B. Johannesen7, B. Rachet1 Cancer Research UK Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK Department of Respiratory Medicine, Glenfield Hospital, Leicester, UK Royal Marsden Hospital, London, UK Juravinski Cancer Centre at Hamilton Health Sciences, Cancer Care Ontario, Toronto, ON, Canada Odense University Hospital, Odense, Denmark Department of Medical Oncology, Sydney Cancer Centre, Royal Prince Alfred Hospital, Sydney, Australia Norwegian Cancer Registry, Oslo, Norway Aim: International differences in lung cancer survival are well known. Using population-based data, we assessed if variation in the provision of treatment may explain some of this variation, focusing on early-stage non-small cell lung cancer (NSCLC) where guidelines recommend resection of curative intent.